| Name | Title | Contact Details |
|---|
GlaxoSmithKline USA is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
sports therapy and rehabilation Inc is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spectranetics is dedicated to managing every lead and eradicating restenosis and amputation. We do this by helping physicians, patients, and hospitals maximize cardiovascular health. Our company is committed to inventing, selling, and supporting technology that enables success during the most challenging minimally invasive cardiovascular procedures. We provide expert physician training, including the only lead removal simulator in the industry, as well as extensive patient and physician education. The Company’s Lead Management (LM) division is dedicated to helping physicians safely manage every lead. We provide the expert tools, training and ongoing support – including the only available lead extraction simulator – that allow physicians precision, control and versatility while extracting leads, so they can focus more on the patient’s overall status while generating positive outcomes. The Vascular Intervention (VI) division is dedicated to helping physicians address the challenges of peripheral and coronary artery disease. We provide expert tools, training, ongoing support, and patient education so that you can help eradicate restenosis and amputation
Liberty HomeCare and Hospice Services is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.